Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Adaptive Phase 2 Trial to Evaluate PL8177 in Hospitalized, Moderate or Severe COVID-19 Adult Subjects with Hypoxemic Respiratory Failure With or Without Mild Acute Respiratory Distress Syndrome (ARDS)

Next Previous
Trial Profile

An Adaptive Phase 2 Trial to Evaluate PL8177 in Hospitalized, Moderate or Severe COVID-19 Adult Subjects with Hypoxemic Respiratory Failure With or Without Mild Acute Respiratory Distress Syndrome (ARDS)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PL 8177 (Primary)
  • Indications Adult respiratory distress syndrome; COVID 2019 infections; Respiratory insufficiency
  • Focus Therapeutic Use
  • Sponsors Palatin Technologies

Most Recent Events

  • 28 Sep 2020 According to a Palatin Technologies media release, considering the risk and uncertainty of conducting COVID-19 clinical studies, the start of this PL8177 clinical study is subject to receiving external funding and operational support. The Company is in the process of applying to government programs that provide such support.
  • 28 Sep 2020 According to a Palatin Technologies media release, Palatin is advancing its COVID-19 development plan and is conducting all the required activities needed to file an IND and begin clinical studies with PL8177 in COVID-19 patients. These activities will be completed in the fourth calendar quarter of 2020, allowing the Company to potentially file an IND with the FDA and initiate this clinical study of PL8177 for the treatment of COVID-19 patients early in the first calendar quarter of 2021.
  • 28 Jun 2020 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top